FDA Inspection 1168630 — Labcorp Drug Development

Labcorp Drug Development — FEI 2242945

The FDA completed an inspection of Labcorp Drug Development on Apr 25, 2022 in Princeton, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Apr 25, 2022
Fiscal Year
2022
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Princeton, NJ (United States)

Additional details

Sponsor, Contract Research Organization

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.